Meanwhile, ATO has been demonstrated to be an inducer of JUN through regulating JNK and MAPK pathways in many cancers, such as bladder cancer [67], prostate cancer [68], NSCLC [69], liver cancer [70] and endometrial cancer [71]. Here, JUN is linked to urinary bladder cancer.